3Racine-Poon L, Botta T, Chang W. Efficacy, pharmacodynamics, and pharmacokinetics of CGP51901, on antiimmunglobulin E Chimeric monoclonal antibody, in patients with seasonal allergic rhinitis[J ]. Clin Pharmacol Ther, 1997,62(6) : 675.
4Zheng NX, Sato H, Adachi I, et al .Pharmacokinetics - pharmacodynamics modelling of DP - 190,1, a novel thromboxane synthetase inhibitor in rabbits, based on an indirect response model[J] .Eur J Drug Metab Pharmacokinet, 1996, 21(4) : 285.
5Rosseau A , Marquet P. Adaptive control methods for the dose individualization of anticancer agents[J] , Chin Pharmacokinet, 2000, 38(4) : 315.
6Niels Fricmodt Moller, How predictive is PK/PD for antibacterial agents [J ]. Int J Anlimicrob Agents, 2002, 19(4) : 333.
7Feiberg LE, Henningsson A, Maas H, et al. Model of chemotherapy- induced myelosuppression with parameter consistency across drugs[J] .J Clin Oncol, 2002,20 (24) :4 713.
8Shliner LB, Steimer JL, Pharmacokinetic/pharmacodynamic modeling in drug development[J] .Annu Rev Pharrnacol Toxicol, 2000,40(1) : 67.
9Theil FP, Guentert TW, Haddad S, et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candadate selection [J ]. Toxicol Lett, 2003,138( 1-2) : 29.
10Hideyoshi H, Shinya I, Yumiko U, et al. Optimization of antitumor effect of liposomally excapsulated doxoru bicin based on simulations by pharmacokinetic/ pharmacodynamic modeling [ J ] . J Controlled Release, 1999,61(1) :93.
2Racine-Poon L,Botta T,Chang W. Efficacy, pharmacodynamics, and pharmacokinetics of CGP51901, on anti-immunglobulin E Chimeric monoclonal antibody, in patients with seasonal allergic rhinitis[J] . Clin Pharmacol Ther, 1997; 62: 675-90
3Hochaus G, Schmidt EW, Rominger KL. Pharmacokinetic/dynamic correlation of pulmonary and cardiac effect of fenoterol in asthmatic patients after different routes of administration[J]. Pharm Res, 1992;9:291-7
4Dingemanse J, H(a)usler J, Gering W, Ihmsen H, Albrecht S. Pharmacokinetic-pharmacodynamic modeling of the EEG effects of RO 48-6791, a new short-acting benzodiazepine, in young and elder subjects[J]. Br J Anaesth, 1997; 79:567-74
5Sun YN, DuBois DC, Almon RR. Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamic of methylprednisolone on glucorticoid recptor down-regulation and tyrosine aminotransferase induction in rat liver[J]. J Pharmacokinet Biopherm,1998;26:619-48
6Derendorf H, Hochhaus G, Mullmann H. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids[J]. J Clin Pharmacol, 1993;33:115-23
7Hartmut D, Bernd M. Modeling of pharmacokinetic/pharmcodynamic (PK/PD) Relationships: Concepts and perspectives[J]. Pharm Res,1999;16: 176-85
8Johan L,Gabrielsson, Daniel L,Weiner. Methodology for pharmacokinetic/pharmacodynemic data analysis[J]. PSTT,1999;2:244-52
9Sun YN, McKay LI, Dubois DC. Pharmacokinetic/pharmacodynamic model for corticosteroid receptor /gene-mediated mechanism[J]. J Pharmacol Exp Ther, 1999; 288:720-8
10Valle M, Garrido MJ, Pavon JM. Pharmacokinetic-pharmcodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-o-desmethyltramadol and (-)-o-desmethyltramadol. In rats[J]. J Pharmacol Exp Ther, 2000; 293: 646-53
